1700 Owens Street
About Nurix, Inc.
Nurix, Inc. is a privately-held San Francisco-based biotechnology company that is focused on bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the protein degradation of the cell. The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding the ubiquitin proteasome system (UPS). Nurix was founded by internationally-recognized experts in the UPS field and is funded by leading life sciences investors, Third Rock Ventures and The Column Group. In September 2015 Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly-evolving field of immune-oncology.
11 articles with Nurix, Inc.
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets
The focus will be on discovering drugs that use the body’s natural protein control processes.
Nurix Launches Collaboration With Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute To Expand Its Drug Discovery Program
Two San Francisco Startups, Element Science And Nurix, Reap Cash From Third Rock Ventures' Rich Funding Round